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Growth and Morbidity of Gambian 
Infants are Influenced by Maternal 
Milk Oligosaccharides and Infant 
Gut Microbiota
Jasmine C. C. Davis1,2, Zachery T. Lewis2,3, Sridevi Krishnan4, Robin M. Bernstein6,7, 
Sophie E. Moore8,9, Andrew M. Prentice9, David A. Mills2,3,5, Carlito B. Lebrilla1,2 & 
Angela M. Zivkovic2,4
Human milk oligosaccharides (HMOs) play an important role in the health of an infant as substrate 
for beneficial gut bacteria. Little is known about the effects of HMO composition and its changes on 
the morbidity and growth outcomes of infants living in areas with high infection rates. Mother’s HMO 
composition and infant gut microbiota from 33 Gambian mother/infant pairs at 4, 16, and 20 weeks 
postpartum were analyzed for relationships between HMOs, microbiota, and infant morbidity and 
growth. The data indicate that lacto-N-fucopentaose I was associated with decreased infant morbidity, 
and 3′-sialyllactose was found to be a good indicator of infant weight-for-age. Because HMOs, gut 
microbiota, and infant health are interrelated, the relationship between infant health and their 
microbiome were analyzed. While bifidobacteria were the dominant genus in the infant gut overall, 
Dialister and Prevotella were negatively correlated with morbidity, and Bacteroides was increased 
in infants with abnormal calprotectin. Mothers nursing in the wet season (July to October) produced 
significantly less oligosaccharides compared to those nursing in the dry season (November to June). 
These results suggest that specific types and structures of HMOs are sensitive to environmental 
conditions, protective of morbidity, predictive of growth, and correlated with specific microbiota.
Breast milk provides nourishment for the developing human infant, but also delivers an assortment of bioactive 
molecules with important developmental and protective functions. Free human milk oligosaccharides (HMOs) 
are abundant components of human milk, with over two hundred identified structures so far1,2. HMOs are com-
posed of glucose (Glc), galactose (Gal), N-acetylglucosamine (GlcNAc), fucose (Fuc), and N-acetylneuraminic 
acid (Neu5Ac) or sialic acid. HMOs contain a lactose (Gal(ß1-4)Glc) core, and enzymes can transfer monosaccha-
rides onto that core with various linkages3. HMOs are not synthesized from a template but are instead formed by 
the action of competing glycosyltransferases, which transfer monosaccharides to form diverse branched and lin-
ear structures, complicating compositional oligosaccharide analysis3. For example, the structure lacto-N-tetraose 
(LNT, Gal(ß1-3)GlcNAc(ß1-3)Gal(ß1-4)Glc) is fucosylated to form lacto-N-fucopentaose I (LNFP I, Fuc(α 1-2)
Gal(ß1-3)GlcNAc(ß1-3)Gal(ß1-4)Glc). HMOs provide a number of benefits to infants, including brain develop-
ment4, acting as decoys for pathogenic bacteria5, and preventing disease and infection6.
HMOs are not digestible by infants and arrive intact to the large intestine, where they play an impor-
tant role in the development of the gut microbiota by nourishing specific bacteria (i.e. acting as prebiotics)7. 
Select Bifidobacterium and Bacteroides species have been shown to consume HMOs8. Infants with 
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bifidobacteria-dominated gastrointestinal tracts have higher resistance to colonization by some pathogens and 
enhanced gut barrier function9–12. Bifidobacteria aid the development of the infant’s innate and acquired immune 
systems, enhancing surveillance and reducing inflammation12–15. Some bifidobacteria are better equipped for 
HMO consumption than others. Bifidobacterium longum subsp. infantis was found to better colonize premature 
infant guts than Bifidobacterium animalis subsp. lactis when given concurrently with human milk, likely due to 
the capacity of B. longum subsp. infantis to consume a wide spectrum of HMOs16–20. B. longum subsp. infantis 
colonization is associated with improved responses to some vaccines, decreased intestinal epithelial permeability, 
and has anti-inflammatory effects on the premature intestine10,12,21.
The effects of HMOs on health are composition- and structure-specific, and HMO composition varies 
between mothers and over time6,22–24. One quality that varies between mothers and has been shown to influence 
the microbiota and health of infants is secretor status25,26. Secretors are individuals who secrete ABH antigens 
in their bodily fluids and can link Fuc in an α (1–2) position on a terminal Gal residue. The α (1-2) fucosyltrans-
ferase is responsible for this linkage and is encoded for by the secretor locus27,28; this genotype can be observed 
phenotypically by analyzing the HMO composition of milk27. Notably, secretor mothers have higher relative con-
centrations of fucosylated HMOs, specifically those with α (1-2) Fuc residues including 2′ -fucosyllactose (2′ FL), 
lacto-N-fucopentaose I (LNFP I), lactodifucotetraose (LDFT), and difucosyllacto-N-hexaose a (DFLNHa), but 
lower relative concentrations of undecorated and sialylated HMO27.
The Gambia provides a special opportunity to observe how large fluctuations in environmental factors due 
to seasonality affect oligosaccharide composition in breast milk and the microbial profile in the infant gastroin-
testinal tract. Due to strong seasonal differences in climate, Gambians experience two distinct seasons during 
the year, a dry season and a wet season. During the dry (“harvest,” November to June) season, food is plentiful, 
energy stores are higher, and disease burden is relatively low; however, during the wet (“hungry,” July to October) 
season, food stores become depleted, rates of infection increase, and farming workload increases. The effects of 
this seasonal dichotomy on health and physiology have been documented across several decades of work in rural 
Gambian populations29. In particular, patterns of weight loss and breast milk output link very closely to the sea-
sonal shifts in workload, food availability, and disease burden30. Similarly, Gambian infants show clear seasonal 
patterns of morbidity, like skin infections and diarrhea, which are much higher during the wet season compared 
to the dry season31,32. Higher rates of morbidity can affect infant growth by redirecting bodily resources toward 
fighting infection or repairing damage rather than growth. By profiling breast milk at three early time points 
during lactation when breast milk is the predominant or sole source of nutrition to the infant, it is possible to 
assess the relationship between seasonal changes in HMO composition and the infant’s microbiome, growth, and 
morbidity status (whether the infant was “sick” or “not sick”, as defined in the Materials and Methods section).
In this study, the HMO composition in the breast milk and the infant gut microbiota of 33 rural Gambian 
mother/infant pairs were profiled at 4, 16, and 20 weeks postpartum and related to growth and morbidity in the 
infants. We also examined HMO composition and gut microbiota to investigate if shifts in milk glycan composi-
tion correlate with the gut microbial community. The aim of this work was to determine whether HMO content 
and composition are influenced by seasonal environmental changes, and whether changes in HMO composition 
are associated with protection from morbidity, improved growth, and with the intestinal microbiome.
Results
Changes in HMOs and microbiota over time. In order to identify shifts in HMO composition over time, 
we first measured the oligosaccharide content of mother’s milk at all three time points. The total oligosaccharide 
amounts significantly decreased from 4 to 20 weeks postpartum (Fig. 1A). Absolute abundances for total HMOs, 
total fucosylation, undecorated HMOs, total sialylation, and fucosylated and sialylated HMOs were significantly 
different between weeks 4 and 16 and weeks 4 and 20 (Fig. 1A). Total fucosylation was only statistically different 
between weeks 4 and 20 (P = 0.02) (Fig. 1A). The relative abundances of each class were not statistically different 
throughout lactation.
The individual HMO structures that were quantified in this study are shown in Table 1. Included are their 
relative abundances at each time point, in how many of the 33 milk samples each structure was found, and 
changes in abundances over the three time points. For the analyses in this study, relative HMO class abundances 
and the relative abundances of individual HMOs that were found in at least 75% of all samples during at least 
two of the three weeks were used. These structures included lacto-N-tetraose, LNT; lacto-N-fucopentaose I 
and lacto-N-fucopentaose III, LNFP I and LNFP III; lacto-N-neotetraose, LNnT; sialyllacto-N-neotetraose, 
LSTc; monofucosyllacto-N-hexaose I and monofucosyllacto-N-hexaose III, MFLNH I and MFLNH III; 
fucosyl-para-lacto-N-hexaose, MFpLNH IV; sialyllacto-N-tetraose (b), LSTb; lacto-N-neohexaose, LNnH; 
difucosyllacto-N-hexaose (a), DFLNHa; lacto-N-hexaose, LNH; difucosyl-para-lacto-N-hexaose II, DFpLNH 
II; difucosyllacto-N-hexaose (b), DFLNHb; 3′ -sialyllactose, 3′ SL; monosaccharide composition 4 hex-
ose:0 fuc:2 GlcNAc:1 Neu5Ac and monosialyllacto-N-neohexaose II, 4021a and S-LNnH II; isomer III 
fucosyl-paralacto-N-hexaose, IFLNH III; and fucosyllacto-N-octaose, F-LNO. Several of these structures with 
known α (1-2) Fuc linkages were used to determine maternal phenotypic secretor status (see Materials and 
Methods section). In this cohort, 12 of the 33 mothers were determined to be non-secretors, with relative α (1-2) 
fucosylation less than 6% of total HMOs for non-secretors. The significant differences found in relative class and 
individual HMO abundances between secretors and non-secretors are shown in Fig. 2. As has been observed 
before, secretor mothers had higher relative concentrations of total fucosylated HMOs, but lower relative concen-
trations of undecorated and sialylated HMOs.
Overall, the gastrointestinal tracts of Gambian infants were consistently dominated by bifidobacteria, which 
represented 68.3% of total bacteria on average (Table 2). Of the 85 samples for which sufficient fecal material was 
available for microbiome investigation, only two samples contained less than 10% bifidobacteria (2.35% of sam-
ples) and only four other samples contained less than 40% bifidobacteria (Fig. 1B). A taxonomic group other 
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than bifidobacteria was the majority bacterial group in only five samples (5.88% of samples) (Fig. 1B). Using 
Bifidobacterium-specific methods (including the BLIR method described in the methods section), we determined 
that 76.9% of the bifidobacteria in the samples were one subspecies, B. longum subsp. infantis (B. infantis), making 
it the most abundant taxon in these Gambian infants (Table 2). The next most abundant bifidobacteria, B. longum 
subsp. longum, accounted for 14.1% of the bifidobacteria in these infants (Table 2). Other significant operational 
taxonomic units (OTUs) in the infants included Streptococcus (7.7%), the Enterobacteriaceae family (5.4%), 
Megasphaera (2.4%), Bacteroides (2.0%), Campylobacter (1.8%), Lactobacillus (1.8%), the Coriobacteriaceae family 
(1.6%), Parabacteroides (1.5%), Prevotella (1.2%), and Veillonella (1.0%). Individual infant microbial profiles changed 
over time (Fig. 1B). Even in the presence of a dominant bifidobacterial population, significant changes in community 
structure were noted in the first weeks of life. For example, the Bacilli class was more abundant at 4 weeks than at 
other time points, the abundances of the Bacteroidetes phylum, Proteobacteria phylum, and Coriobacteriia class 
were higher at 16 weeks, and the Clostridia class was enriched at 20 weeks compared to other time points (Fig. 1C).
Associations with infant morbidity. In order to compare mothers’ HMO profiles between infants 
who had sick days with those who did not have sick days (see Supplementary Table 1), Mann-Whitney U with 
Steel-Dwass post hoc tests were performed. Relative abundances for all HMO classes and individual HMOs that 
were found in at least 75% of all samples during at least 2 of the 3 weeks were compared. Mothers of infants 
who were sick at week 16 produced milk with higher relative amounts of LNT than mothers with infants who 
were not sick (P = 0.05), but those same mothers with sick infants produced significantly lower levels of LNFP 
I and III (P = 0.02) (Fig. 3). Relative abundances of F-LNO at week 4, MFpLNH IV at week 16, and IFLNH 
III at week 16 were found to be higher in infants who were sick compared to those who were not sick (see 
Supplementary Fig. S1). There were no statistically significant differences in HMO profiles in relation to reported 
morbidity at week 20.
Similarly, linear discriminant analysis (LDA) effect size (LefSe) analysis was used to determine which bacteria 
were associated with reported morbidity. Levels of the most abundant taxon, bifidobacteria, were not significantly 
different between infants who were sick and not sick. Though they were minor members of the community, 
higher levels of Dialister and Prevotella were found in infants whose mothers reported their infant was not sick, 
while increased (but still low) amounts of unidentified Burkholderiales and Aeromonadaceae were associated 
with sickness (Fig. 4A and Supplementary Fig. S2).
Associations between fecal calprotectin and HMO and the gut microbiota were also assessed. For these 
analyses, infant calprotectin levels were used as continuous values and also binned into normal (< 50 mg/kg), 
borderline (50–120 mg/kg), and abnormal (> 120 mg/kg) categories using published cutoffs33–35. Multiple 
Figure 1. Changes over time in human milk oligosaccharides (HMOs) and microbiota. (A) Changes in 
human milk oligosaccharides (HMOs) and microbiota from week 4 ( ) to week 16 ( ) to week 20 ( ) 
postpartum. Absolute abundances of HMOs show a decrease for all classes: total oligosaccharides, total 
fucosylated HMO, undecorated HMO, total sialylated HMO, and fucosylated and sialylated HMO. P-values for 
differences between time points are denoted by * for P < 0.001, § for P < 0.0001, and  for P < 0.00001 based on 
linear mixed effects models. Undecorated HMO abundances were log transformed and P-values are based on 
transformed data. (B) Microbiota composition for each infant at one or more time points. The most abundant 
genus across all samples was Bifidobacterium (green bar). (C) Cladogram of microbiota enriched at each time 
point with results based on LefSe analysis. Bacilli were enriched at week 4 ( ), Bacteroidetes, Proteobacteria, 
and Coriobacteriia were enriched at week 16 ( ), and Clostridia were enriched at week 20 ( ).
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linear regression stepwise models were created with relative class and individual HMO and microbiota to 
predict infant fecal calprotectin levels at each week. Microbiota with an average relative abundance of at least 
1% were also used (Bifidobacterium, Streptococcus, the Enterobacteriaceae family, Megashpaera, Bacteroides, 
Campylobacter, Lactobacillus, the Coriobacteriaceae family, Parabacteroides, Prevotella, and Veillonella). No sig-
nificant models were found for either HMO or microbiota to predict calprotectin values, whether used as a con-
tinuous or categorical value. Calprotectin levels were, however, significantly higher at week 4 than week 16 (see 
Supplementary Fig. S3).
As the composition of the microbiota would be predicted to influence fecal calprotectin levels, individual bac-
terial species were screened against the calprotectin class of the infants. Though the abundance of the major bac-
terial group in these infants (bifidobacteria) did not differ by the infant’s calprotectin level, a few lower abundance 
species were associated with the calprotectin level. Several members of the Pseudomonadales order (Acinetobacter 
and Pseudomonas) and Vagococcus were associated with normal (low) fecal calprotectin levels, while unidentified 
Leuconostocaceae and Bacteroides were associated with abnormal (high) fecal calprotectin levels (Fig. 4B and 
Supplementary Fig. S4).
Structure
Relative Abundance (%) Number of Samples Found In
Week 4 Week 16 Week 20 Week 4 Week 16 Week 20
LNTa,b 23.8 21.3 22.7 33 33 33
LNFP I + III 10.3 10.5 10.2 25 29 28
LNnT 8.68 10.9 10.7 18 26 25
LSTca,b,c,d 4.86 3.26 3.76 33 33 33
MFLNH I + IIIb 3.82 2.87 3.23 24 29 32
MFpLNH IV 2.57 3.71 2.93 32 30 31
LSTb 2.29 3.19 3.16 33 33 33
LNnH 2.44 2.46 2.32 33 33 33
DFLNHa 2.48 2.14 2.50 30 30 28
LNHa,b,c,d 3.50 1.72 1.67 33 31 33
DFpLNH II 1.68 2.81 2.20 27 27 28
DFLNH bc,d 1.24 2.19 2.71 28 25 25
3′ SLb,c,d 0.776 1.25 1.38 33 33 33
4021a + S-LNnH II 1.19 1.07 0.986 32 28 29
IFLNH III 1.03 1.03 1.01 31 29 29
F-LNO 0.712 0.522 0.527 29 26 26
2′ FL 7.66 11.8 9.85 22 23 25
LNDFH II 3.55 3.34 3.97 19 23 21
LDFT 1.97 4.27 3.88 24 24 25
4120a 2.16 3.46 2.51 16 11 14
TFLNH 1.52 1.80 1.72 18 18 18
p-LNH 1.69 1.57 1.36 23 21 23
F-LSTc 1.16 1.48 1.16 23 18 19
LNDFH I 0.547 1.34 0.907 5 9 10
5130a 1.36 0.669 0.726 27 22 22
5230a + DFLNnO I/DFLNO II 0.968 0.592 0.652 26 24 24
5330a 0.741 0.700 0.647 17 10 11
IFLNH I 0.709 0.621 0.721 22 20 20
DFLNnO II 1.01 0.468 0.550 28 23 23
DFLNO I 0.842 0.571 0.548 27 18 20
5130b 0.673 0.518 0.420 16 8 8
S-LNH 0.815 0.305 0.356 33 15 15
LSTa 0.341 0.355 0.431 24 25 25
LNFP II 0.355 0.362 0.318 18 22 21
6′ SL 0.370 0.288 0.243 26 16 15
DFLNHc 0.237 0.204 0.322 13 5 6
5130c 0.277 0.283 0.200 17 6 9
4320a 0.224 0.247 0.217 8 5 6
3FL 0.164 0.263 0.249 9 15 14
Table 1.  Identified HMO structures and their relative abundances at each time point. aSignificant 
differences in absolute abundances between week 4 and week 16. bSignificant differences in absolute abundances 
between week 16 and week 20. cSignificant differences in relative abundances between week 4 and week 16. 
dSignificant differences in relative abundances between week 16 and week 20.
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Associations with infant growth. Weight-for-age Z scores (WAZ) and height-for-age Z scores (HAZ) 
were calculated against a Gambian reference for the infants at all time points (see Supplementary Table 2). AUC 
over the 4, 16, and 20 week time points was calculated using the Trapezoidal rule for relative abundances of HMO 
classes and the individual structures that were found in at least 75% of samples for at least 2 time points. The abil-
ity of the HMO AUCs to predict WAZ and HAZ scores at 20 weeks was determined using multiple linear regres-
sion stepwise models. The model for WAZ at 20 weeks showed a significant overall P-value of 0.8 × 10−6; the AUC 
for the relative abundance of 3′ SL had a positive contribution while LSTc had a negative contribution (Table 3). 
DFLNHa and LNFP I and III had positive contributions to HAZ at 20 weeks (P = 0.05) (Table 3). As shown in the 
cladogram (see Supplementary Fig. S5), which indicates the microbes enriched in each group colored according 
to the legend, LEfSe results for the microbiota and infant growth indicate that several members of class Bacilli 
were enriched in stunted infants, and Adlercreutzia and Klebsiella were enriched in wasted infants (see Materials 
and Methods section for binning).
Associations with seasonal fluctuations. Mothers displayed significant variation in their total oligo-
saccharide abundance based on the season they were nursing in. Mothers who gave birth during the wet season 
appeared to maintain their total HMO production after 20 weeks of lactation, producing higher amounts of 
total HMOs than mothers who gave birth during the dry season (Fig. 5A). After 20 weeks postpartum, how-
ever, all mothers who gave birth during the wet season were nursing in the dry season and vice versa for those 
who gave birth during the dry season. Mothers nursing in the dry season produced significantly higher abun-
dances of total HMOs compared to mothers nursing in the wet season (Fig. 5B). Based on LefSe analysis the 
lower-abundance taxa, Bacilli, Flexispira, and Mollicutes were more prevalent in babies born in the wet season 
(see Supplementary Fig. S6).
Associations between HMOs and infant microbiota. Correlation plots were used to determine the 
relationships among the HMO abundances and the top 12 most abundant microbiota (along with the relative 
abundances of B. infantis and B. longum subsp. longum to the fecal microbiota as a whole) (Fig. 6). Irrespective of 
time, Prevotella and B. infantis had negative correlations with sialylated structure LSTc. B. infantis was the only 
microbe that was positively correlated with LNnT abundance. B. longum subsp. longum was negatively correlated 
with total fucosylation, but Lactobacillus had a positive relationship with total fucosylation. Lactobacillus also had 
a positive association with absolute LNFP I and III. Coriobacteriaceae and Megasphaera had negative correlations 
with total sialylation, fucosylated and sialylated, and LNT, and Coriobacteriaceae also had a negative correla-
tion with total HMOs. Streptococcus had positive correlations with total sialylation, fucosylated and sialylated, 
and LSTc. Campylobacter had a negative correlation with LNT. Parabacteroides had a positive relationship with 
MFLNH I and III and IFLNH III.
Predicting microbiota functions. In order to investigate the potential mechanism by which the above dif-
ferences in taxonomic profiles might influence community metabolic potential and/or host biology, PICRUSt was 
Figure 2. Differences in relative human milk oligosaccharide (HMO) classes and individual structure 
abundances between secretors and non-secretors. Differences in relative human milk oligosaccharide (HMO) 
class and structure abundance between phenotypic secretors (S, , N = 21) and non-secretors (N-S, , 
N = 12). Plots show averages for all mothers divided by time point (week 4, 16, and 20) with error bars 
representing standard error and P-values listed below each plot for overall differences based on Mann-Whitney 
U tests. Individual HMO structures pictured with monosaccharides Glc ( ), Gal ( ), GlcNAc ( ), Fuc ( ) 
and Neu5Ac ( ).
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used to predict the functional profile of the community. A total of 6909 functions were predicted to be possessed 
by the combined OTUs in this sample set. After false discovery rate (FDR) correction no functions were found to 
be significantly different (P ≤ 0.05) between infants with different clinical levels of calprotectin, fed by mothers 
of different secretor status, or reported as sick versus non-sick (data not shown). However, three functions were 
found to change over early life: K00844: hexokinase [EC:2.7.1.1], K01036: butyrate-acetoacetate CoA-transferase 
[EC:2.8.3.9], and K01615: glutaconyl-CoA decarboxylase [EC:4.1.1.70] (see Supplementary Fig. S7). On average, 
the levels of these three functions increased as a proportion of the predicted infant fecal metagenomes over the 
first 20 weeks of life. The major microbes that were found to contribute these functions (mostly Bacteroidales and 
Clostridiales such as Megasphaera) are shown in Supplementary Table 1.
Discussion
The results from this study suggest that HMOs consumed by infants and the associated microbiota both 
impact infant health outcomes. These associations with proxy health measures in the present study comprise 
context-specific correlations, which at present have only theoretical causational support. However, this study is 
valuable as an initial hypothesis-generating screen from which to direct future research efforts into mechanisms. 
The data indicate that mothers of infants who had zero sick days (reported instance(s) of diarrhea, fever, rash, 
coughing, etc.) produced milk with lower relative amounts of LNT and higher relative amounts of LNFP I and III 
compared to mothers of infants who had sick days. Isomers LNFP I and III could not be chromatographically sep-
arated during analysis, but since LNFP III is < 5% the abundance of LNFP I, discussion was focused on LNFP I5. 
LNFP I is the fucosylated version of LNT, with Fuc in an α (1-2) linkage on the terminal Gal. F-LNO at week 4 and 
MFpLNH IV and IFLNH III at week 16 were also different between sick and not sick infants, but these fucosylated 
structures were found at higher relative abundance in the sick infants. The Fuc linkage on all three of these struc-
tures is α (1-3), unlike LNFP I which is an α (1-2) linkage, and they are found at much lower abundance (less than 
5%) than LNFP I which makes up around 12% of HMOs. Total relative fucosylation was not significantly different 
between sick and not sick infants. Previous studies have also shown that higher consumption of α (1-2) linked Fuc 
led to lower experiences of diarrhea26. Newburg et al. showed a decreased incidence of diarrhea in infants who 
consumed milk with higher ratios of α (1-2) linked Fuc compared to HMOs with α (1-3/4) linked Fuc26. Previous 
studies have found 2′ -fucosyllactose (2′ FL, Fuc(α 1-2)Gal(ß1-4)Glc) to be associated with reduced diarrhea inci-
dence caused by Campylobacter jejuni, an infant gastrointestinal pathogen36–38. In this study we did not observe 
any statistically significant associations between reported morbidity and 2′ FL. Instead, our results showed that it 
was the α (1-2) fucosylation of LNT to LNFP I that was associated with lower morbidity. Together, these findings 
point to specific roles for different α (1-2) fucosylated structures in the protection from morbidity.
OTU
Average 
Abundance (%)
k__Bacteria;p__Actinobacteria;c__Actinobacteria;o__Bifidobacteriales;f__Bifidobacteriaceae;g__Bifidobacterium 68.3
k__Bacteria;p__Firmicutes;c__Bacilli;o__Lactobacillales;f__Streptococcaceae;g__Streptococcus 7.72
k__Bacteria;p__Proteobacteria;c__Gammaproteobacteria;o__Enterobacteriales;f__Enterobacteriaceae;g__ 5.41
k__Bacteria;p__Firmicutes;c__Clostridia;o__Clostridiales;f__Veillonellaceae;g__Megasphaera 2.37
k__Bacteria;p__Bacteroidetes;c__Bacteroidia;o__Bacteroidales;f__Bacteroidaceae;g__Bacteroides 2.02
k__Bacteria;p__Proteobacteria;c__Epsilonproteobacteria;o__Campylobacterales;f__Campylobacteraceae;g__Campylobacter 1.80
k__Bacteria;p__Firmicutes;c__Bacilli;o__Lactobacillales;f__Lactobacillaceae;g__Lactobacillus 1.78
k__Bacteria;p__Actinobacteria;c__Coriobacteriia;o__Coriobacteriales;f__Coriobacteriaceae;g__ 1.55
k__Bacteria;p__Bacteroidetes;c__Bacteroidia;o__Bacteroidales;f__Porphyromonadaceae;g__Parabacteroides 1.51
k__Bacteria;p__Bacteroidetes;c__Bacteroidia;o__Bacteroidales;f__Prevotellaceae;g__Prevotella 1.25
k__Bacteria;p__Firmicutes;c__Clostridia;o__Clostridiales;f__Veillonellaceae;g__Veillonella 1.02
k__Bacteria;p__Proteobacteria;c__Betaproteobacteria;o__Burkholderiales;f__Alcaligenaceae;g__Sutterella 0.461
k__Bacteria;p__Firmicutes;c__Clostridia;o__Clostridiales;f__[Mogibacteriaceae];g__ 0.407
k__Bacteria;p__Firmicutes;c__Bacilli;o__Lactobacillales;f__Enterococcaceae;g__Enterococcus 0.315
k__Bacteria;p__Firmicutes;c__Bacilli;o__Bacillales;f__Staphylococcaceae;g__Staphylococcus 0.187
k__Bacteria;p__Firmicutes;c__Erysipelotrichi;o__Erysipelotrichales;f__Erysipelotrichaceae;g__ 0.170
k__Bacteria;p__Firmicutes;c__Clostridia;o__Clostridiales;f__;g__ 0.148
k__Bacteria;p__Verrucomicrobia;c__Verrucomicrobiae;o__Verrucomicrobiales;f__Verrucomicrobiaceae;g__Akkermansia 0.132
k__Bacteria;p__Proteobacteria;c__Betaproteobacteria;o__Neisseriales;f__Neisseriaceae;g__Neisseria 0.131
k__Bacteria;p__Firmicutes;c__Bacilli;o__Lactobacillales;f__Aerococcaceae;g__Facklamia 0.111
k__Bacteria;p__Tenericutes;c__Mollicutes;o__Mycoplasmatales;f__Mycoplasmataceae;g__ 0.0771
All Others 3.15
Bifidobacerial species B. adolescentis B. animalis B. breve
Unidentified  
B. longum group
B. longum subsp. 
infantis
B. longum 
subsp. longum
B. bifidum/B. 
pseudocatenulatum Unknown
Percent of total bifidobacteria 0 0.0127 0.941 2.22 76.9 14.1 5.69 0.179
Table 2.  Relative abundances of the most prevalent microbiota over the infants’ first 20 weeks of life.
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Figure 3. Differences in individual human milk oligosaccharide (HMO) structures between infants who 
were “sick” or “not sick” at week 16. Differences in individual human milk oligosaccharides (HMOs) between 
infants who had reported sick days (Sick, ) and those who did not (Not Sick, ). Plots are divided by sick and 
not sick infants, displaying week 16 average and standard error bars for relative abundances of (a) LNT (lacto-
N-tetraose) and (b) LNFP I and III (lacto-N-fucopentaose I and lacto-N-fucopentaose III). HMO structures 
pictured with monosaccharides Glc ( ), Gal ( ), GlcNAc ( ), and Fuc ( ) with the enzyme listed for the 
creation of LNFP I from LNT. N for each group are given above the respective groups and P-values are listed 
below each plot based on Mann-Whitney U tests.
Figure 4. Differences in microbiota between infants who were reported to be “sick” or “not sick” and 
different calprotectin levels. Plot showing the linear discriminant analysis (LDA) scores for the enriched 
microbiota based on infant morbidity outcomes. (a) Score for microbiota that were found to be enriched in 
infants who were reported to have sick days (Sick, ), and those who were reported to have no sick days (Not 
Sick, ). (b) Score for the microbiota that were found to be enriched in infants who had normal ( ) or 
abnormal ( ) calprotectin levels. Calprotectin categories were created using published cut-offs for normal and 
abnormal levels.
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Statistical models were used to predict WAZ and HAZ scores at 20 weeks as a response to the HMO abun-
dances. Relative 3′ SL (Neu5Ac(α 2-3)Gal(ß1-4)Glc) was the strongest model predictor, contributing positively 
to WAZ, meaning the higher the proportion of 3′ SL produced by the mother from 4 to 20 weeks, the larger her 
infant’s WAZ score at 20 weeks was. LSTc (Neu5Ac(α 2-6)Gal(ß1-4)GlcNAc(ß1-3)Gal(ß1-4)Glc), on the other 
hand, contributed negatively to WAZ at 20 weeks. Relative total sialylation was not a predictor. As with the pos-
itive associations between α (1-2) but not α (1-3) fucosylated structures and morbidity, again here, an α (2-3) 
but not an α (2-6) sialylated species was associated with better growth. Infants from a Malawian cohort who 
were severely stunted at 6 months postpartum had mothers who produced significantly less sialylated HMO 
than mothers with infants of healthy height39, agreeing with our findings here of a positive association between 
sialylated HMO and growth. Increased weight gain was also observed in model mice and piglets fed diets with 
supplemented sialylated bovine milk oligosaccharides, mainly 3′ SL and 6′ SL (Neu5Ac(α 2-6)Gal(ß1-4)Glc)39.
In addition to 3′ SL, LNFP I was also found to contribute positively to growth, in this case HAZ, at 20 weeks. 
As indicated earlier, LNFP I was found at higher abundance in the milk of infants who did not have sick days. 
These findings suggest that LNFP I may help infants maintain growth by sparing resources that would otherwise 
be redirected toward fighting off infection. Whether these changes in relative concentration of LNFP I are indic-
ative of upregulation of the FUT2 gene, its activity, and/or other compositional changes in milk that are then 
responsible for protecting the infant from infection, or whether LNFP I directly protects the infant by binding and 
inactivating pathogens in the intestine, needs to be determined in future studies.
The mothers’ HMO profiles were significantly affected by the seasonal changes experienced in The Gambia. 
Prentice et al. showed that during the dry season, lactating mothers had an increased energy intake compared 
to mothers lactating in the wet season, which could explain the ability of mothers to produce milk with higher 
concentrations of HMOs when nursing in the dry season40. Previous research has also shown seasonal variation 
in overall milk output, not just HMO output, with a reduced amount of milk consumption during the wet season, 
concomitant with a higher risk for infection and growth failure in infants born during the wet season41,42. HMO 
production decreases throughout lactation, but there could be a potentially larger decrease in HMO output by 
mothers nursing in the wet season at 20 weeks postpartum due to their reduced caloric intake. This could be 
detrimental to their infant’s growth and morbidity status. It is important to note, however, that as the infant 
grows older he/she consumes a higher total volume of milk per day and therefore the total dose of oligosaccha-
rides per day may remain consistent, although they are consuming a less concentrated milk. Total volume of 
Parameter
Final model predictors 
(Log transformed) Coefficient F statistic Multiple R2 Overall P-value
WAZ
%3′ SL 1.7886
7.808 0.3374 0.8 × 10−6
%LSTc − 1.1185
HAZ
%LNFP I + III 0.5670
2.459 0.0947 0.05
%DFLNHa 0.4995
Table 3.  Multiple Linear Regression stepwise models used to predict weight-for-age (WAZ) and height-
for-age (HAZ) Z scores at 20 weeks postpartum.
Figure 5. Comparison of mother’s total human milk oligosaccharide (HMO) production by infant birth 
season and 20 weeks postpartum. Box plots of total human milk oligosaccharides (HMO) production at 
20 weeks postpartum compared by (a) infant birth season and (b) what season mothers were living in 20 
weeks postpartum. All mothers who gave birth during the wet season were living in the dry season 20 weeks 
postpartum, and all mothers who gave birth during the dry season were living in the wet season 20 weeks 
postpartum. Mothers lactating in the wet season produced less total HMO during that time point compared 
to mothers lactating in the dry season during that time point. In both plots the median is given as a line, the 
25th and 75th percentiles are the top and bottom of the boxes, and the whiskers are data within 1.5*(75th–25th 
percentile) of the median. N for each group are given above the respective groups and P-values are listed below 
each plot based on Mann-Whitney U tests.
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milk consumed by each infant was not measured in this study. Although the majority of infants were exclusively 
breast-fed through 20 weeks, the introduction of semisolid foods and water could also affect milk intake and milk 
composition. The mechanisms by which a seasonal energy deficit in the mother is translated to HMO production 
levels in the mammary gland are currently unknown and deserve further study to better understand how infant 
needs are communicated to the mother to alter milk composition to meet those needs.
In this study we chose to analyze the HMO data as relative rather than absolute abundances of HMO, because 
as noted above, the total amount of milk consumed by each infant each day was not measured, therefore the 
total abundance of HMO consumed by each infant could not be calculated. However, we also focused on relative 
abundances because we were interested in how changes in the composition of HMOs affect health outcomes. 
The compositional differences are indicative of fluxes through the glycosyltransferase pathways. For example, an 
increased relative concentration of the fucosylated structure LNFP I with a concomitant decrease in the relative 
concentration of its precursor LNT is indicative of an increased flux in α (1-2) fucosylation. The increased α 
(1-2) fucosylation of specific HMO in this cohort was associated both with protection from morbidity and with 
improved growth. Mechanistic studies are needed to understand how seasonal, dietary, environmental, genetic, 
and/or other factors influence the ability of the mammary gland to turn on α (1-2) fucosylation in an individual 
mother to increase protection of the infant from infection. Similar mechanisms may be involved in the regulation 
of the production of sialylated structures and growth.
As observed in other cohorts of infants from less-developed countries like Venezuela, Bangladesh, and 
Malawi, bifidobacteria (and specifically B. infantis) were the dominant microbe in this group of infants10,43,44. B. 
infantis possesses a large genetic complement of enzymatic tools to consume the major human milk glycans in 
breast milk, suggesting that the dominance of the gut community by this microbe is driven by the availability of 
Figure 6. Correlation matrix results of associations among absolute HMO abundances and most prevalent 
microbiota. Pearson’s correlations between absolute abundances of total human milk oligosaccharides (HMOs), 
HMO classes (Total Fuc, Total Sial, Undecorated HMOs, and Fuc + sial), and the individual HMOs found in at 
least 75% of samples for at least two time points (LNT, lacto-N-tetraose; LNFP I + LNFP III, lacto-N-
fucopentaose I + lacto-N-fucopentaose III; LNnT, lacto-N-neotetraose; LSTc, sialyllacto-N-neotetraose; 
MFLNH I + MFLNH III, monofucosyllacto-N-hexaose I + monofucosyllacto-N-hexaose III; MFpLNH IV, 
fucosyl-para-lacto-N-hexaose; LSTb, sialyllacto-N-tetraose (b); LNnH, lacto-N-neohexaose; DFLNHa, 
difucosyllacto-N-hexaose (a); LNH, lacto-N-hexaose; DFpLNH II, difucosyl-para-lacto-N-hexaose II; 
DFLNHb, difucosyllacto-N-hexaose (b); 3′ SL, 3′ -sialyllactose; 4021a + S-LNnH II, monosaccharide 
composition 4 hexose:0 fuc:2 GlcNAc:1 Neu5Ac + monosialyllacto-N-neohexaose II; IFLNH III, fucosyl-
paralacto-N-hexaose III; and F-LNO, fucosyllacto-N-octaose), and the most abundant infant microbiota. Infant 
microbiota data in the first two columns (% B. infantis and % B. longum) are calculated from a combination of 
the Bifidobacterial-specific -terminal restriction fragment length polymorphism, Bifidobacterium Longum-
Infantis Ratio (BLIR), and 16S sequencing analysis as described in the methods section, while microbiota data 
in the remaining columns are from the 16S sequencing analysis alone. Values highlighted in red ( ) indicate 
significant positive correlations (P ≤ 0.05) and plots highlighted in green ( ) indicate significant negative 
correlations (P ≤ 0.05).
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these substrates17,19,20. Indeed, in this study, we found that B. infantis was the only (sub)species positively corre-
lated with LNnT, which represented ~10.1% of total HMO. The observed shifts in microbial community compo-
sition over time (class Bacilli being more abundant at 4 weeks, the Bacteroidetes phylum, Proteobacteria phylum, 
and Coriobacteriia class more common at 16 weeks, and the Clostridia class more abundant at 20 weeks) may 
represent the succession of species more acclimated to environmental conditions promoted by weaning from 
an exclusively breast milk diet, and/or changes in the microbial exposure of the infant as he/she starts to move 
and sample their environment. Of the 23 infants whose microbiota was measured at all three time points, seven 
had received water, cow’s milk, and/or semisolid food by week 20. Three infants were also fed from a bottle for 
some of their meals rather than feeding at the breast, which could also contribute to bacterial diversity at 20 
weeks. Initially colonizing Lactobacilli (of possible vaginal origin) present at 4 weeks may be replaced by both 
Bacteroides species able to consume select HMOs and by species that can use the metabolic end products of the 
dominant bifidobacteria45,46. A shift toward higher amounts of Clostridia is also associated with the consumption 
of weaning foods47,48.
Colonization by bifidobacteria has been associated with proxies for desirable infant health outcomes such 
as higher resistance to pathogen colonization, improved response to some vaccines, better gut barrier function, 
enhanced immune surveillance, and reduced inflammation9,10,12–15. However, we found no correlations between 
bifidobacteria levels and morbidity, likely because of the ubiquity of bifidobacteria in this cohort. We did find, 
however, that infants who did not have sick days had higher Prevotella, which agrees with a previous study in a 
cohort of children from Malawi44. Although there were too few such cases in this cohort of 33 infants to allow 
for statistical analysis, several infants had large shifts in the total amount of bifidobacteria at certain time points, 
which coincided with changes in growth patterns and/or morbidity measures. For example, infant 25 started out 
with over 60% bifidobacteria at weeks 4 and 16, which fell to less than 10% bifidobacteria and was largely replaced 
by Enterobacteriaceae at week 20. Although she had not had any sick days at either week 4 or week 16, at week 20 
this infant had 12 sick days, a very high calprotectin level (867.67 mg/kg), and lost weight from week 16 to week 
20. Following a similar pattern, the relative abundance of LNFP I in her mother’s milk went from 24% at week 4 
to 18% at week 16, to a very low level of 0.1% at week 20. At the same time, the relative abundance of 2′ FL stayed 
about the same (12%, 12%, 11%), whereas the relative abundance of LNT increased from 15% at week 4, to 26% 
at week 16 and 23% at week 20. The overall composition of milk decreased 12% in fucosylated structures but 
increased 10% in undecorated HMOs. Percent sialylation varied from 12% at week 4 to 9% at week 16 to 17% at 
week 20. In this particular case, the infant was born in the dry season, but mother and infant transitioned into the 
wet season in week 16 and were still in the wet season at week 20. These findings indicate that significant shifts in 
the mother’s HMO milk composition coincided with both the shifts in the infant’s gut microbiota and with the 
infant’s growth and morbidity outcomes (see Supplementary Fig. S8). They also highlight the seasonally-driven 
shifts in resource availability for mothers, and again point to LNFP I as a potentially important indicator of health 
outcomes.
Our finding that Bacteroides was increased in those infants who had high fecal calprotectin levels is intrigu-
ing in light of several recent reports. High levels of Bacteroides colonization are common in many of the cohorts 
of infants from developed countries studied so far, and are more common in vaginally-delivered infants25,49,50. 
Whereas B. infantis is specifically specialized to consume a broad array of HMOs17,51,52, Bacteroides species are 
also able to consume at least some HMOs, though select bifidobacteria outcompete Bacteroides for these carbon 
sources46. Our results demonstrate that in the background of a dominant bifidobacterial population, increas-
ing amounts of Bacteroides species are associated with increased neutrophil-related gut inflammation as meas-
ured by fecal calprotectin levels. Vatanen et al. showed that Bacteroides presence may expose infants to increased 
amounts of lipopolysaccharide (LPS) types which are linked to downstream autoimmune disease by inhibiting 
the immune-stimulating effects of E. Coli derived LPS53. It is unknown whether the Bacteroides species present 
in the Gambian infants studied here possessed LPS types similar to the Bacteroides dorei studied by Vatanen et al. 
Bacteroides degradation products of sialylated milk oligosaccharides have been shown to promote the growth of 
inflammation-inducing (and potentially pathogenic) Enterobacteriaceae in in vitro studies, however we did not 
detect an enrichment of enterobacteria in infants with abnormally high calprotectin levels39,54,55.
Our data show a positive correlation between Lactobacillus and fucosylated structures; an observation sup-
ported by a study showing that Lactobacillus casei BL23 contains genes encoding fucosidases which were capable 
of degrading fucosylated oligosaccharides56. Other lactobacilli, however, such as Lactobacillus delbrueckii and 
L. rhamnosus show very little growth on 2′ FL57. Our findings of positive correlations between Streptococcus and 
total sialylation, fucosylated and sialylated structures, and LSTc match a report that several strains of Streptococcus 
have been shown to produce sialidases58. Other streptococci strains, however, are negative for sialidase activity59. 
B. longum subsp. longum was negatively correlated with fucosylated HMO, confirming previous observations25. 
B. longum subsp. longum is likely less efficient at consuming fucosylated HMOs due to its lack of 
HMO-consumption related genes, including fucosidases, thus higher breast milk fucose content would be pre-
dicted to lead to lower colonization by B. longum subsp. longum19. B. infantis was the only microbe that was 
found to be positively correlated with LNnT, which confirms previous reports that B. infantis grows very well on 
this particular HMO species18. Thus the ability of the microbiome to degrade certain types of oligosaccharides is 
dependent on the specific strains comprising the infant’s microbiota. This strain variability may contribute to our 
failure to find functional differences in the microbiomes between infants fed by mothers of different secretor sta-
tus using the predictive tool PICRUSt, as it is dependent on the specific sequenced strains available in public data-
bases. Other factors must be taken into consideration when discussing the significance of these associations, such 
as cross-feeding between strains, growth of certain taxa on other microbial by-products, the influence of other 
breast milk components, and the fact that a known HMO-consuming bifidobacterial strain was dominant in the 
majority of these infants. Although our sequencing-based results do not test the HMO-consumption-related 
metabolic abilities and low-level enzymatic functions of the specific microbial species present in these infants, 
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the correlations we present are in many cases consistent with the known abilities of studied strains. However, we 
cannot rule out the hypotheses that these observations are due to unrelated microbe-microbe interactions or 
co-correlation with a third factor rather than direct consumption of HMOs by the correlated microbe.
To evaluate the impact of microbial differences between classes of infants, the functional abilities of the fecal 
microbiome were predicted using PICRUSt. While no significant differences were found that might explain 
infant growth or health outcomes, three functions were found to increase over time. One of these functions, 
butyrate-acetoacetate CoA-transferase, can be involved in butyrate metabolism, and in the context of infant gas-
trointestinal tracts is likely involved in utilizing the larger concentrations of bifidobacterial-derived acetate pres-
ent in the environment45,60–63. The largest contributor of this function was the Veillonellaceae. This shift likely 
reflects the maturation of the microbiome community as selective pressures assert themselves and niches are filled 
by better-adapted species.
Together these results lead us to conclude that changes in milk HMO composition, as well as shifts in the 
infant’s gut microbiota are both associated with infant health outcomes in The Gambia. Specifically, the rel-
ative abundance of LNFP I, the α (1-2) fucosylated structure of the parent compound LNT, was found to be 
higher in infants who did not have sick days compared to those who had sick days, and was also predictive of 
HAZ score at 20 weeks, suggesting that this HMO may be either directly or indirectly involved in protecting the 
infant from infection and thus promoting growth. The α (2-3) sialylated structure 3′ SL was predictive for infant 
weight-for-age. Our findings suggest that specific HMOs and/or specific glycosyltransferase pathways can alter 
the composition of milk toward a more protective profile which is associated with lower rates of infection/inflam-
mation, and which allow the infant to invest energy in growth. In this cohort, as with other cohorts in similar 
countries, infant gastrointestinal tracts were dominated by bifidobacteria. We were not able to detect statistically 
significant effects of shifts in bifidobacteria abundance because for most infants bifidobacteria levels stayed high 
(on average about 70% of total bacteria) across all three time points, although in five out of seven cases when 
bifidobacteria levels dropped significantly, there were concomitant increases in morbidity and/or growth falter-
ing, as well as large shifts in HMO profiles. Prevotella was associated with decreased morbidity. In this study, we 
found that the seasonal fluctuations in energy availability in The Gambia affected the mother’s ability to produce 
HMOs such that mothers lactating during the wet (hungry) season had larger decreases in total HMOs over time 
than mothers lactating during the dry season. How the overall health, environment, and diet of the mother affects 
the quality of her milk and thus the ability of her milk to protect her infant from infection and promote growth 
is an important question to resolve in future studies. Mechanisms involved in mediating the protective effects of 
HMO profiles and specific HMO structures on infant morbidity and growth also need to be further studied, as do 
the gut microbiota-specific pathways involved in mediating these effects.
Materials and Methods
Experimental Design. The samples analyzed were from a sub-study embedded within a randomized 
trial to investigate the effects of pre-natal and infancy nutritional supplementation on infant immune devel-
opment, The Early Nutrition and Immune Development (ENID) Trial, ISRCTN49285450, http://www.isrctn.
com/ISRCTN49285450)64, registered on December 11, 2009. Ethical approval for the ENID Trial and the 
‘ENID-Bioactives’ sub-study was obtained from the joint Gambian Government/MRC Unit The Gambia Ethics 
Committee and the George Washington University Institutional Research Board (#13-0441). Full informed 
consent was obtained from each participant, prior to inclusion in the study. Samples were collected from 200 
Gambian mother-infant pairs at weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 postpartum. Breast 
milk collection, infant anthropometry measurements, and infant morbidity data were collected according to a 
study design described previously64,65 and in accordance with relevant guidelines and regulations. Five mL of 
hand-expressed milk was collected from each breast into a separate tube in the morning during regular study 
visits at the Keneba clinic and the participants’ homes then stored at − 80 °C. Mothers collected their infant’s fecal 
samples from a disposable diaper into a collection pot that was provided. The pot was then placed in a cold box 
with an ice pack and given to study personnel, who then delivered the sample to the Keneba clinic laboratory 
where samples were stored at − 70 °C. Fecal samples were then freeze-dried for 24 hours and stored at − 20 °C. 
For this study, a subset of 33 mothers and infants with samples at 4, 16, and 20 weeks was selected. After milk and 
fecal samples were shipped to UC Davis they were stored at − 80 °C until analysis. Height, weight, and morbidity 
data of the infants were recorded weekly. Mothers self-reported morbidity data as observed incidents of illness for 
their infant. The days of illness for all of the disease categories were summed to create a new continuous variable 
of total number of sick days for each week. The number of sick days for each milk collection time point was cal-
culated by summing the number of sick incidents for the four weeks surrounding that time point. Because milk 
composition changes over time, the four surrounding weeks were used to provide the best representation of how 
the HMO composition affected morbidity during that time frame. These values were used as a categorical value, 
designated as “sick” (if there were any sick days) or “not sick” (if there were no sick days during that time) (see 
Supplementary Table 2). Weight was measured using portable digital scales (Seca 334) with infants in minimal 
clothing. Length was measured using a portable length board (Seca 417). All measures were recorded in triplicate 
using standard protocols, and equipment was regularly calibrated. The weight and height of each infant at every 
time point were used to calculate weight-for-age (WAZ) and height-for-age (HAZ) Z scores based on a Gambian 
reference (see Supplementary Table 3). These scores were also grouped into categorical variables; infants with 
Z scores < − 2 were deemed “underweight” or “stunted,” respectively, and those with scores > − 2 were “desired 
weight” or “not stunted”66. See Supplementary Table 4 for further mother and infant clinical data.
Infant Fecal DNA Extraction and Analysis. DNA extraction. DNA was extracted from the freeze-dried 
fecal samples using the ZR Fecal DNA MiniPrep Kit, (Zymo Research, Irvine, CA, USA) according to the manu-
facturer’s instructions. This included a bead-beating step using a FastPrep-24 Instrument (MP Biomedicals, Santa 
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Ana, CA) for 2 minutes at 25 °C at a speed of 6.5 m/s. In a few cases, the default amount of lysis solution (750 μ l) 
was insufficient to reconstitute the freeze-dried samples, and the addition of more (up to the capacity of the tube) 
was necessary to fully rehydrate the samples. Only 85 of the samples contained enough fecal matter to extract 
DNA for an analysis of the gut microbiota.
Sequencing and analysis. Illumina sequencing—V4 region: DNA extractions were prepared for marker 
gene sequencing as previously described67 with the following modifications. Universal barcoded prim-
ers with Illumina sequencing adapters (adapters are italicized and the barcode is highlighted in bold) 
V4F (5′  -AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT 
ACTGCTGAGTGTGCCAGCMGCCGCGGTAA-3′ ) and V4Rev ( 5′ - C A A G C A G A A G A C G G C A T A C G A G A T C 
 G G T C T C GG C A T T C C T G C T G A A C CG C T CT TC CG ATCTCCGGACTACHVGGGTWTCTAAT-3′ ) w er e u se d t o 
P CR amplify the V4 region of the 16S rRNA gene67. PCR reactions contained 7.5 μ l 2x GoTaq Green Master Mix 
(Promega, Madison, WI), 0.6 μ l 25 mM MgCl2, 3.6 μ l water, 1.5 μ l forward and 0.3 μ l reverse primers (0.2 μ M final 
concentration), and 1.5 μ l DNA. A negative control was also included into which water was added in the place of 
DNA. A portion of each reaction was electrophoresed in a 0.8% agarose gel and stained with GelGreen (Phenix, 
Candler, NC). The DNA band for each sample was visually categorized by brightness and size for quality control. 
All samples were pooled (5 μ l of each reaction for samples with bright bands, 10 μ l for faint samples with bands, 
and 12 μ l for samples with non-visible bands) and purified with the QIAquick PCR Purification Kit (QIAGEN, 
Valencia, CA) according to the manufacturer’s instructions. The pooled, purified amplicons were sequenced at 
the University of California-Davis DNA Technologies Core Facility on an Illumina MiSeq sequencing platform. 
A negative control was also included. The raw sequencing data and accompanying metadata were deposited in 
the European Nucleotide Archive under accession number ERP017462, and the Qiita database under Study ID 
10297.
Sequence Analysis. The QIIME software package (version 1.8.0) was used to analyze the results of the Illumina 
sequencing run. llumina V4 16S rRNA gene sequences were demultiplexed and quality filtered using the QIIME 
1.8 software package with default settings unless otherwise specified67. Reads were truncated after a maximum 
number of 3 consecutive low quality scores. The minimum number of consecutive high quality base calls to 
include a read (per single end read) as a fraction of the input read length was 0.75. The minimum acceptable 
Phred quality score was set at 20. Similar sequences were clustered into operational taxonomic units (OTUs) 
using open reference OTU picking with UCLUST software68. Taxonomy was assigned to each OTU with the 
Ribosomal Database Project (RDP) classifier69 and the RDP taxonomic nomenclature70. OTU representatives 
were aligned against the Greengenes core set71 with PyNAST software72.
Bif-TRFLP (terminal restriction fragment length polymorphism). A Bifidobacterium-specific termi-
nal restriction fragment length polymorphism assay was performed as previously described73. DNA from 
feces was PCR amplified using primers NBIF389 (5′ -74-GCCTTCGGGTTGTAAAC) and NBIF1018 REV 
(GACCATGCACCACCTGTG). The Qiagen Qiaquick PCR purification kit DNA was used to clean the DNA, 
which was then cut with restriction enzymes AluI and HaeIII. The resulting fragments were analyzed on an 
ABI 3100 Capillary Electrophoresis Genetic Analyzer at the UC Davis College of Biological Sciences Sequencing 
Facility and compared against the published database for species identification.
Bifidobacterium Longum-Infantis Ratio (BLIR). The BLIR method was used to quantify the relative amounts of two 
B. longum subspecies25. PCR was performed on the fecal DNA using three primers (FWD_BL_BI (5′ -74-AAAACGT 
CCATCCATCACA), REV_BL (5′ -ACGACCAGGTTCCACTTGAT), and REV_BI (5′ -CGCCTCAGTTCT 
TTAATGT)) targeting a conserved portion of the genome (between Blon_0424 and Blon_0425) shared by both 
subspecies. FWD_BL_BI is complementary to a sequence in both subspecies while REV_BL and REV_BI are 
complementary to nearby sequences in only B. longum subsp. longum and B. longum subsp. infantis, respectively. 
FWD_BL_BI and REV_BL amplify a fragment of the B. longum spp. longum genome 145 bp in length, while 
FWD_BL_BI amplify a fragment of the B. longum subsp. infantis genome 114 bp in length.
DNA from each sample was amplified by PCR using 0.5 μ l of 10 μ M stock of each of the above primers, 12.5 μ l 
GoTaq Green Master Mix (Promega), 1 μ l of 25 mM MgCl2, 1 μ l of template DNA, and 9 μ l of nuclease free water. 
Cycling conditions were 95 °C for 2 minutes, 30 cycles of 95 °C for 1 minute, 54 °C for 1 minute, and 72 °C for 
30 seconds, followed by a 72 °C extension for 5 minutes. PCR products were purified from the mixture using the 
QIAquick PCR purification kit (Qiagen) and diluted 1:10. 1.5 μ l of the dilutions were analyzed on an ABI 3100 
Capillary Electrophoresis Genetic Analyzer at the UC Davis College of Biological Sciences Sequencing Facility. 
The samples were analyzed with PeakScanner 2.0 software (Applied Biosystems, Carlsbad, CA) to quantify peak 
area of amplicons from each subspecies. A positive control was included with each PCR run to ensure potential 
amplification of both B. longum subsp. longum and B. longum subsp. infantis products.
Calprotectin Measurements. Intestinal inflammation was indexed by measuring infant fecal calprotectin 
levels. A commercial ELISA kit (Phical; CALPRO AS) was used, with the protocol adjusted for use on freeze-dried 
infant feces75. Calprotectin levels were also binned into three categories based on previously developed clinical 
diagnoses: normal (less than 50 mg/kg), borderline (50–120 mg/kg), and abnormal (greater than 120 mg/kg)33–35.
HMO Extraction and Analysis. HMO extraction. Free HMOs were extracted from whole breast milk 
samples following previously reported methods5,27,76–78. 50 μ L of each milk sample was aliquotted onto 96-well 
plates, diluted, and defatted via centrifugation. The resulting glycans were reduced with 1.0 M NaBH4 in a water 
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bath at 65 °C for 1.5 hours. The samples were then purified on solid phase extraction graphitized carbon car-
tridges (GCC). HMO samples were loaded onto the GCCs, desalted with deionized water, and eluted with 20% 
acetonitrile in water and then 40% acetonitrile in 0.05% trifluoroacetic acid (v/v). The eluent fractions were com-
bined and the solvent evaporated. After reconstitution, the samples were diluted to appropriate concentration for 
analysis.
Nano-HPLC-Chip/TOF Mass Spectrometry. Analysis of the extracted HMOs was performed on a nano-high 
performance liquid chromatography (HPLC)-chip/time-of-flight (TOF) mass spectrometer. The Agilent 1200 
series HPLC (Agilent Technologies, Santa Clara, CA) unit incorporates a capillary pump for sample loading 
and a nano pump for analyte separation, done on a microfluidic chip. The chip contains a 40 nL enrichment 
column and a 75 μ L × 43 mm analytical column packed with porous graphitized carbon. The HMO samples were 
loaded onto the enrichment column (1 μ L injection) by the capillary pump at a flow rate of 4.0 μ L/min. Separation 
was achieved with a binary gradient of aqueous solvent A (3% acetonitrile/water (v/v) in 0.1% formic acid) and 
organic solvent B (90% acetonitrile/water (v/v) in 0.1% formic acid). The method developed and optimized for 
separating HMO mixtures by Wu et al. was used5,77. This system is coupled to an Agilent 6220 series TOF mass 
spectrometer via chip-cube interface. Data was collected in the positive mode, and the instrument was calibrated 
by a dual nebulizer electrospray source with internal calibrant ions ranging from m/z 118.086 to 2721.895.
HMO Data Processing. Data was collected and analyzed using Agilent MassHunter Qualitative Analysis soft-
ware, versions B.02.01 and B.03.01, respectively. HMO compounds were identified using the Find Compounds 
by Molecular Feature function, and an in-house program was used for peak alignment. Specific structures were 
identified and assigned by matching retention time and exact mass, within 20 ppm mass error, to theoretically 
calculated masses in previously developed annotated HMO libraries5,77. Absolute abundances in ion counts were 
directly correlated to the abundance of the compounds present. Glycan types were divided into four classes: 
fucosylated (any structure with Fuc), sialylated (any structure with Neu5Ac), fucosylated and sialylated, and 
undecorated. To determine the relative abundance of each class, abundances were divided by the total oligosac-
charide count for each mother. The same calculation was performed to find relative abundances for individually 
identified compounds. Forty-three distinct structures were identified. If the peak abundance of an isomer could 
not be integrated separate from another closely eluting peak, those peak abundances were summed and the two 
structures grouped together.
Secretor Status Determination. The method used in this study for determining phenotypic secretor sta-
tus was modified from a previously developed method for determining secretor status27. Absolute abun-
dances of compounds with known α (1-2) linked Fuc (2′ -fucosyllactose (2′ FL), lactodifucotetraose (LDFT), 
trifucosyllacto-N-hexaose (TFLNH), difucosyllacto-N-hexaose a (DFLNHa), difucosyllacto-N-hexaose c 
(DFLNHc), and isomer I fucosyl-paralacto-N-hexaose (IFLNH I)2,5) were summed and normalized to each 
mother’s total oligosaccharide abundance to calculate relative α (1-2) fucosylation for mothers at all time points. 
Mothers with less than 6% relative α (1-2) fucosylation were assigned as phenotypic non-secretors; assigned secre-
tor status was consistent at all time points.
Statistical Analyses. HMO Analyses. All statistical analyses were done in R statistical software, unless 
specified otherwise (R core team, Vienna Austria). P ≤ 0.05 was considered significant. Absolute and relative 
oligosaccharide class and structure abundances were obtained for the 33 mothers at all 3 time points (N = 99). 
Analyses were performed using the abundances of HMO classes and individual structures found in at least 
75% of all samples during at least two of the time points: LNT, LNFP I and III, LNnT, LSTc, MFLNH I and 
III, LSTb, MFpLNH IV, LNnH, LNH, DFLNHa, DFpLNH II, DFLNH b, 3′ SL, 4021a and S-LNnH II, IFLNH 
III, and F-LNO. To determine if there were differences between secretors and non-secretors and infants who 
were “sick” and “not sick,” non-parametric Mann-Whitney U tests were performed on relative class abundances 
and relative abundances for the previously listed individual HMOs. Generalized Linear Mixed Effects modeling 
(GLME), using weeks as a repeated measure and the subjects as random effects, were used (N = 99) to determine 
differences across lactation weeks. Where appropriate, Tukey’s posthoc tests were used to identify individual 
differences. The Bartlett test was used to check for equal variance for all HMO class abundances; values were log10 
transformed to meet homoscedasticity requirements for ANOVA tests. Pearson’s correlation analyses were used 
to determine associations between top twelve most abundant microbiota, relative B. longum subsp. longum and 
B. longum subsp. infantis with absolute HMO abundances (N = 85) using JMP Pro 12.1 (SAS Institute, Cary, NC). 
Area under the curve (AUC) for all data were calculated using the trapezoidal method. The AUC for relative class 
abundances and relative individual HMO structures listed above were entered into a stepwise linear regression 
model (backwards using AIC criterion) to determine which among these variables best predict variation in HAZ 
and WAZ scores at week 20.
Microbiota Analyses. Only 85 of the total 99 samples contained enough fecal matter to extract DNA for an analysis 
of the gut microbiota. The marker gene sequencing data was tested using LefSe (LDA Effect Size) with default set-
tings (unless otherwise noted) to investigate differences between classes of samples79. For PICRUSt, the OTU table 
from QIIME was filtered to contain just the closed-reference-picked OTUs and normalized by predicted 16S copy 
numbers. The KEGG Ortholog (KO) metagenome was then predicted by PICRUSt using the predict_metagenomes.
py script80. The resulting KO table was then investigated for differences in the predicted functional profile of the 
fecal microbiome between classes of samples using the Statistical Analysis of Metagenome Profiles (STAMP) imple-
mentation of the Kruskal-Wallis H-test with a Benjamini-Hochberg False Discovery Rate (FDR) correction81,82.
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